Answers are grounded in this paper and cite their sources.
Low density lipoprotein (LDL)-apheresis is an approved chronic maintenance therapy for thelowering of plasma cholesterol (LDL reduction >60%) in patients with uncontrolledhypercholesterolemia caused by familial hypercholesterolemia and resistance topharmacotherapy. Clinical studies have demonstrated its benefit in the reduction ofcardiovascular disease. LDL-apheresis can lower other pathological mediators of vasculardisease, such as inflammation, hemorrheology, thrombosis and fibrinolysis. The acute andchronic pleiotropic effects of LDL-apheresis on these vascular markers might warrant its usein more diverse settings of vascular disease. This review discusses currently approvedLDL-apheresis procedures, the guidelines for their use and current and future therapeuticapplications of the technique.
No takes yet. Share an insight, caveat, or question.
Patrick M. Moriarty (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: